Clinical Trial Update: Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC

View source ↗

Summary

A completed clinical trial evaluating whether inflammatory markers ICC and MCVL can predict response to nivolumab in metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Dr. Lutfi Kirdar Kartal Training and Research Hospital | Conditions: Metastatic Renal Cell Carcinoma | Status: COMPLETED